Abstract
Background The binary major depressive disorder (MDD) diagnosis is inadequate and should never be used in research.
Aims The study’s objective is to explicate our novel precision nomothetic strategy for constructing depression models based on adverse childhood experiences (ACEs), lifetime and current phenome, and biomarker (atherogenicity indices) scores.
Methods This study assessed recurrence of illness (ROI: namely recurrence of depressive episodes and suicidal behaviors), lifetime and current suicidal behaviors and the phenome of depression, neuroticism, dysthymia, anxiety disorders, and lipid biomarkers (including ApoA, ApoB, free cholesterol and cholesteryl esters, triglycerides, high density lipoprotein cholesterol) in 67 normal controls and 66 MDD patients. We computed atherogenic and reverse cholesterol transport indices.
Results We were able to extract one factor from a) the lifetime phenome of depression comprising ROI, and traits such as neuroticism, dysthymia and anxiety disorders, and b) the phenome of the acute phase (based on depression, anxiety and quality of life scores). PLS analysis showed that 55.7% of the variance in the lifetime + current phenome factor was explained by increased atherogenicity, neglect and sexual abuse, while atherogenicity partially mediated the effects of neglect. Cluster analysis generated a cluster of patients with major dysmood disorder, which was externally validated by increased atherogenicity and characterized by increased scores of all clinical features.
Conclusions The outcome of depression should not be represented as a binary variable (MDD or not), but rather as multiple dimensional scores based on biomarkers, ROI, subclinical depression traits, and lifetime and current phenome scores including suicidal behaviors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Ratchadapisek-sompotch Fund, Faculty of Medicine, Chulalongkorn University (Grant number GA64/21), a grant from the Graduate School and H.M. the King Bhumibhol Adulyadej 72nd Birthday Anniversary Scholarship Chulalongkorn University, both to KJ, and the FF60 grant and Sompoch Endowment Fund from the Faculty of Medicine, MDCU to MM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant national and international privacy and ethical guidelines were followed during the research. The study was approved by the Chulalongkorn University Medical Faculty's Institutional Review Board (#445/63) in Bangkok, Thailand. Prior to participating in the study, all subjects were asked to voluntarily fill out a consent form with detailed information about their participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
e-mail addresses: dr.michaelmaes{at}hotmail.com; ket.kett{at}hotmail.com; asara.vasu{at}gmail.com; b_patchaya{at}yahoo.comchavit.t{at}chula.ac.th
Data Availability
The dataset that was made and/or analysed during this study will be available from the corresponding author (MM) once it has been fully used by the authors and a reasonable request has been made.
